Angelini Pharma lures Gilead exec to be its new CEO

22 November 2022

Italy-based privately-owned Angelini Industries has appointed Jacopo Andreose as chief executive (CEO) of its subsidiary Angelini Pharma, a position he will take up starting from February 6, 2023.

Mr Andreose has a wealth of experience in top roles within the pharmaceutical industry: he comes from Gilead Sciences (Nasdaq: GILD), where he held the role of senior vice president, Intercontinental Region, with direct responsibility for the business in Asia, Latin America, the Middle East, Africa, Eastern Europe. Previously, Mr Andreose worked at GlaxoSmithKline (LSE: GSK)/ViiV Healthcare, Bristol Myers Squibb and Abbott, covering growing strategic and operational roles in Italy, the USA, Europe and Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK